Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment
Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its second-generation siRNA candidate, SIL-204. The findings reveal ... Read More
Merck secures exclusive global license for opevesostat from Orion Corporation
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an ... Read More
AstraZeneca acquisition of Fusion Pharmaceuticals receives shareholder approval
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.'s shareholders have overwhelmingly voted in favor of the proposed acquisition by AstraZeneca. During a ... Read More